Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by Kevin Kalinsky, Columbia University
Sponsor:
Collaborators:
Incyte Corporation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Kevin Kalinsky, Columbia University
ClinicalTrials.gov Identifier:
NCT02066532
First received: February 18, 2014
Last updated: May 18, 2017
Last verified: May 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)